Pfizer Inc. (PFE: News ) said Friday the U.S. Food and Drug Administration approved its kidney cancer drug Inlyta to treat patients with advanced renal cell carcinoma who failed a standard treatment.
The approval follows an unanimous recommendation by a FDA panel last month that Inlyta (Axitinib) had a favorable benefit-risk profile.
Regards,
Don

![[del.icio.us]](http://pennystockdd.com/wp-content/plugins/bookmarkify/delicious.png)
![[Digg]](http://pennystockdd.com/wp-content/plugins/bookmarkify/digg.png)
![[Faves]](http://pennystockdd.com/wp-content/plugins/bookmarkify/faves.png)
![[LinkedIn]](http://pennystockdd.com/wp-content/plugins/bookmarkify/linkedin.png)
![[Reddit]](http://pennystockdd.com/wp-content/plugins/bookmarkify/reddit.png)
![[StumbleUpon]](http://pennystockdd.com/wp-content/plugins/bookmarkify/stumbleupon.png)
![[Technorati]](http://pennystockdd.com/wp-content/plugins/bookmarkify/technorati.png)





